Filter

521 - 530 of 800 Results

  • A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration

    Issue Brief

    This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in the previous Congress that may return to the forefront of health policy discussions in the coming years.

  • Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2022

    Issue Brief

    This issue brief provides an overview of the Medicare Part D prescription drug benefit market for 2022, with a primary focus on stand-alone drug plans. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D drug plans available in 2022.

  • FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries

    Issue Brief

    The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implications for Medicare and beneficiaries associated with Biogen's new FDA-approved Alzheimer's drug, which will cost $56,000 per year.

  • A New Analysis Takes a Closer Look at Online Contraception Platforms Amid the Pandemic

    News Release

    Even prior to the COVID-19 pandemic, hormonal contraception became more accessible to many outside of traditional clinical settings through websites or apps that offer contraception via telehealth. To better understand this emerging method of contraceptive access, a new KFF analysis provides a deeper look at telecontraception platforms, offering insights into the practices of 13 different companies based on information collected between November 2020 through January 2021. Key highlights from the report include: All of the…

  • Toplines: July/August 2005 Health Poll Report Survey

    Poll Finding

    Health News Index July/August, 2005 These toplines provide the complete survey questions and responses to the July/August 2005 Kaiser Health Poll Report, a bimonthly report designed to provide key tracking information on public opinion about health care topics to journalists, policymakers and the general public. It includes a series of questions on seniors' views and knowledge about the Medicare prescription drug benefit. Topline/Survey

  • Choosing a Medicare Part D Plan: Are Medicare Beneficiaries Choosing Low-Cost Plans?

    Report

    Since 2006, Medicare beneficiaries have had the opportunity to choose from among dozens of plans to get the Part D prescription drug benefit, facing wide variation in benefits, premiums and cost-sharing. The array of choices, with more than 50 stand-alone drug plans in many states, could allow beneficiaries to select a plan that provides the best value for their individual medical and economic needs. This study uses actual pharmacy claims experiences, and premium and cost-sharing…

  • Prospects for Retiree Health Benefits as Medicare Drug Coverage Begins – Report

    Report

    Prospects for Retiree Health Benefits as Medicare Drug Coverage Begins:Findings from the Kaiser/Hewitt 2005 Survey on Retiree Health Benefits - Report This report assesses how large businesses that provide retiree health benefits to their workers are responding to the new Medicare drug benefit in 2006, their plans for the future, and the way these responses affect retirees. It also looks at the rising costs and changing benefits of retiree health coverage overall in 2005. Full…

  • Hispanics and the New Medicare Drug Benefit

    Poll Finding

    In a few short weeks, Medicare will undergo big changes that will have a major impact on more than 3 million Hispanic seniors and younger people with permanent disabilities who rely on Medicare for their health coverage. More than one in three Hispanics with Medicare lack coverage for their prescription drugs for at least part of the year. Many others will need to make decisions about their existing coverage and the new Medicare benefit. Starting…

  • The Role of Clinical and Cost Information in Medicaid Pharmacy Benefit Decisions: Experience in Seven States

    Issue Brief

    This policy brief provides perspective on the potential for using comparative effectiveness research in Medicaid pharmacy programs by looking at seven states to determine how they currently evaluate relative clinical and cost information about prescription drugs when making coverage decisions for their Medicaid pharmacy benefits. The brief was prepared by researchers at the Foundation's Kaiser Commission on Medicaid and the Uninsured and Avalere Health. Policy Brief (.pdf)

  • Illustrating the Potential Impacts of Adverse Selection on Health Insurance Costs in Consumer Choice Models

    Other Post

    Health Care Spending in the United States and OECD Countries  Health spending is rising faster than incomes in most developed countries, which raises questions about how these countries will pay for future health care needs.  The issue may be particularly acute in the United States, which not only spends much more per capita on health care than any other country, but which also has had one of the fastest growth rates in health spending among…